F. Hoffmann-La Roche (manufacturing unpackaged products, quality control testing at release (microbiological purity); batch release)

The drug is indicated for the treatment of adult patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation, in combination with vemurafenib.

Dosage form: tablets, film-coated

ATC: L01EE02